Tariffs Work Great — If You're Big Pharma

The Trump administration is preparing to announce tariffs of up to 200 percent on imported patented drugs as soon as Thursday. If you are a pharmaceutical executive, the interesting document is not the tariff order. It is the list of companies that already negotiated their way out of it.

Fifteen of the 17 largest pharmaceutical manufacturers have signed pricing agreements with the administration, securing multi-year exemptions from the penalties, according to Reuters. Pfizer committed $70 billion in U.S. research and manufacturing investment in exchange for a three-year reprieve, according to Mintz, a Washington policy firm. AstraZeneca, Johnson & Johnson, Eli Lilly, and Merck followed, according to Reuters, with Eli Lilly's publicly disclosed U.S. manufacturing commitment totaling $27 billion. The companies that have not yet signed are the ones still exposed when the announcement lands.

The tariff weapon is real. Section 232 of the Trade Expansion Act of 1962 gives the Commerce Department authority to impose penalties on imports deemed a national security risk, and the administration has prepared an order that would hit branded medications and their active ingredients at 100 percent, STAT News reported. Bloomberg reported that the tariff range could extend from 100 percent to 200 percent for companies without agreements. The U.S. Chamber of Commerce has estimated that a 25 percent tariff on all imported medicines would cost the pharmaceutical industry roughly $50 billion annually, equivalent to 13 percent of the sector's domestic sales in a normal year. The rates being floated now are four to eight times that.

But the tariff is not the policy. The tariff is the club. The actual policy is the TrumpRx platform, launched in February with five manufacturer partners including AstraZeneca, Eli Lilly, and Pfizer, and designed to tie U.S. market access to pricing concessions that would not show up in foreign reference markets until after the agreement terms expire.

The exemptions tell you how the administration reads corporate leverage. Pfizer was first through the door, and it paid the largest publicly disclosed price: $70 billion in domestic commitments, a figure large enough to be a political headline rather than a surgical negotiation. AstraZeneca and J&J came next, then the rest of the major manufacturers. The companies that moved earliest got the most defined terms. The companies still negotiating are either smaller, more exposed to specific foreign markets they cannot easily sacrifice, or hoping the announcement is the peak pressure rather than the beginning of it.

The U.S. pharmaceutical supply chain is a geopolitical artifact that nobody in the industry has ever seriously tried to undo. The United States produces approximately 12 percent of active pharmaceutical ingredient volume, despite accounting for a far larger share of final drug consumption, according to the US Pharmacopeia, a nonprofit that sets drug quality standards. India and the European Union are the dominant API hubs for U.S. prescriptions, with the EU specifically accounting for 43 percent of branded pharmaceutical API, according to the same USP data. China contributes roughly 8 percent of total API volume by quantity but dominates the key starting materials that sit upstream of most manufacturing chains, meaning the actual dependency is deeper than the tonnage numbers suggest. Generic drugs account for 90 percent of U.S. prescription fills. The drugs that are hardest to source domestically are generically the most commoditized, which is precisely why the manufacturing base migrated abroad decades ago.

A 100 percent tariff on imported drugs would hit generics and branded products differently. Generics have thin margins and limited pricing power; a doubling of input costs cannot be absorbed and cannot easily be passed through to insurers. Branded manufacturers have more pricing flexibility and, under the TrumpRx framework, have already negotiated the exemptions that make the headline rate largely irrelevant to their U.S. operations. The tariff would fall hardest on the segment of the market least able to absorb it, which is also the segment that makes up the vast majority of what Americans actually pick up at the pharmacy.

The existing drug shortage list makes this concrete. There were 214 drugs in active shortage as of late 2025, according to AJMC, which covers the drug supply chain. The FDA has documented recurring shortages of chemotherapy agents, antibiotics, and Attention Deficit Hyperactivity Disorder medications driven in part by manufacturing concentration and supply chain fragility. A tariff structure that raises input costs for the lowest-margin manufacturers while leaving the largest players exempt does not obviously fix the shortage problem. It may deepen it.

The administration has signaled that rates could go higher still. Legal analysts tracking the Section 232 filings have reported that the White House has floated 150 to 250 percent tariffs as a future escalation step for companies that refuse to negotiate. The Commerce Department initiated the underlying national security investigation in April 2025 under the Trade Expansion Act of 1962, a law that gives the president broad authority to adjust imports found to threaten domestic industrial capacity. The invocation of national security for a finished pharmaceutical product is unusual; the administration appears to be using it as a legal on-ramp rather than a substantive finding.

The companies that have not yet signed agreements with TrumpRx are not in a strong position to hold out. Most have limited manufacturing flexibility. Domestic capacity expansion takes years and billions of dollars. The companies that folded first had enough U.S. exposure to make the math of compliance more attractive than the math of resistance. The ones still outside the tent are largely there because they have less to trade or less ability to move quickly. The tariff announcement is not going to change their calculus in a direction that favors waiting.

What the exemption pattern actually demonstrates is that the administration's pharmaceutical pricing strategy works, at least in the narrow sense of bringing manufacturers to the table on terms the White House defines. The companies that complained loudest about foreign freeloading are the same companies that paid to join the program. Whether that program delivers lower prices for American patients or primarily transfers political risk from the administration to manufacturers is a different question, and one the announcement of tariffs on the holdouts will not answer.

The thing to watch is what happens to the drugs that are already in shortage, and whether the exemption structure is actually designed to solve the supply problem or simply to demonstrate that the administration can make pharmaceutical companies do things. The answer will arrive in the shortage data in six to twelve months, assuming the shortages do not get worse first.

---

† † Source-reported; not independently verified.

---

† † Source-reported; not independently verified.